Datasheet: HCA252

Description:	HUMAN ANTI TOCILIZUMAB
Specificity:	TOCILIZUMAB
Other names:	ACTEMRA®, ROACTEMRA®
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD21362
Isotype:	HuCAL Fab monovalent
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA (1)	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

(1) **NB. The Rat anti DYKDDDDK-tag antibody, clone 6F7 is not suitable for use with this antibody as clone 6F7 exhibits cross reactivity with the human IL-6R**

Product Form

A monovalent human recombinant Fab (kappa light chain) selected from the HuCAL® phage display library, expressed in *E. coli.* The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.

Buffer Solution

Phosphate buffered saline

Preservative Stabilisers

0.01% Thiomersal

Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

Immunogen

Tocilizumab

Specificity

Human anti Tocilizumab, clone AbD21362 is a paratope specific, anti-idiotypic antibody that binds to free tocilizumab but not to human Interleukin-6 Receptor (IL-6R) or the drug/IL-6R complex. The antibody can be used to measure the levels of tocilizumab and biosimilar products in bioanalytical assays.

Clone AbD21362 can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the capture antibody, paired with the detection antibody

	clone AbD21338_hIgG HRP-conjugated and in full immunoglobulin (Ig) format (HCA253). Tocilizumab, marketed under the brand name RoActemra® in Europe and Actemra® in North America, is a humanized IgG1/kappa monoclonal antibody approved for the treatment of moderate to severe rheumatoid arthritis and for the treatment of systemic juvenile idiopathic arthritis. The therapeutic antibody is directed against IL-6R and acts by blocking the binding of IL-6R (both the soluble form, sIL-6R, and the membrane bound form, mIL-6R) to IL-6, thus impeding the pro-inflammatory properties of this cytokine. View a summary of all anti-tocilizumab antibodies
Affinity	The monovalent intrinsic affinity of this antibody was measured as K_D=0.9 nM by real time, label-free molecular interaction analysis on immobilized tocilizuimab.
ELISA	This product may be used in a direct or indirect ELISA or as a capture reagent in a PK bridging ELISA together with HCA253 as the detection reagent. Protocol: PK bridging ELISA to measure free drug
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use
Shelf Life	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Actemra® and RoActemra® are registered trademarks of Hoffman-La Roche and Chugai Pharmaceuticals co., Ltd. His-tag is a registered trademark of EMD Biosciences.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Secondary Antibodies

Mouse Anti Synthetic Peptide HISTIDINE TAG (MCA5995...) HRP

Recommended Useful Reagents

HISPEC ASSAY DILUENT (BUF049A)
LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK001P)

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK002P)
LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK003P)
LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK004P)
LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK005P)
LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK006P)
HUMAN ANTI TOCILIZUMAB (HCA253)
HUMAN ANTI TOCILIZUMAB (HCA254)
HUMAN ANTI TOCILIZUMAB (HCA255)
HUMAN ANTI TOCILIZUMAB (HCA256)
HUMAN ANTI TOCILIZUMAB (HCA257)

North & South America
Tel: +1 800 265 7376
Fax: +1 919 878 3751
Email: antibody_sales_us@bio-rad.com

Worldwide
Tel: +44 (0)1865 852 700
Fax: +44 (0)1865 852 739
Email: antibody_sales_uk@bio-rad.com

Europe
Tel: +49 (0) 89 8090 95 21
Fax: +49 (0) 89 8090 95 50
Email: antibody_sales_de@bio-rad.com

'M311343:171113'

Printed on 01 May 2018

© 2018 Bio-Rad Laboratories Inc | Legal | Imprint